Part D/Medicaid price differentials
Rep. Henry Waxman (D-Calif.) asks the Government Accountability Office to examine price differences for individual drugs under the Medicare Part D and Medicaid programs in a Jan. 27 letter. Waxman asserts that the transition of Medicaid/Medicare dual-eligible beneficiaries to Part D will "likely result in a multi-billion dollar windfall for drug manufacturers." In particular, Waxman asks GAO to investigate whether drug prices paid by PDPs are higher than Medicaid "best price," determine the magnitude of the differential cost for individual drugs, and estimate the total magnitude of the costs differences in 2006 and over the next 10 years...
You may also be interested in...
Twenty-seven percent of the various drug products used by Medicare Part D enrollees are subject to manufacturer rebates that reduce their price, according to a survey of the leading 12 Part D insurance providers
Two European pharmaceutical companies, UCB and Merck KGaA, are exploring artificial intelligence in different ways, the first for drug discovery and the second on a fundamental level.
The final text brings some changes, including the introduction of an escalation process when companies and NHS England cannot agree.